JIANGSU KANION PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.05 CNY | -1.33% |
|
+2.19% | -2.29% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,739 | 6,030 | 7,055 | 10,961 | 11,999 | 11,707 | - | - |
| Enterprise Value (EV) 1 | 9,016 | 6,030 | 7,055 | 10,961 | 11,999 | 11,707 | 11,707 | 11,707 |
| P/E ratio | 17.1 x | 23.1 x | 21.9 x | 25 x | 22.1 x | 17.8 x | 15.1 x | 12.7 x |
| Yield | 0.54% | - | - | - | 1.8% | 1.95% | 2.09% | 2.24% |
| Capitalization / Revenue | 1.91 x | 1.99 x | 1.93 x | 2.52 x | 2.46 x | 2.02 x | 1.75 x | 1.53 x |
| EV / Revenue | 1.91 x | 1.99 x | 1.93 x | 2.52 x | 2.46 x | 2.02 x | 1.75 x | 1.53 x |
| EV / EBITDA | 11.7 x | - | 13 x | 16.9 x | 15.9 x | 14.2 x | 9.82 x | 10.3 x |
| EV / FCF | - | - | - | - | 16.1 x | 50.5 x | 13 x | 12.7 x |
| FCF Yield | - | - | - | - | 6.21% | 1.98% | 7.71% | 7.9% |
| Price to Book | 2.22 x | - | 1.64 x | 2.31 x | 2.31 x | 2.01 x | 1.83 x | 1.64 x |
| Nbr of stocks (in thousands) | 592,881 | 592,881 | 576,429 | 584,598 | 584,748 | 583,899 | - | - |
| Reference price 2 | 14.74 | 10.17 | 12.24 | 18.75 | 20.52 | 20.05 | 20.05 | 20.05 |
| Announcement Date | 4/9/20 | 4/9/21 | 3/3/22 | 2/20/23 | 3/10/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,566 | 3,032 | 3,649 | 4,351 | 4,868 | 5,786 | 6,694 | 7,660 |
| EBITDA 1 | 746.3 | - | 542.1 | 648.3 | 754.5 | 822 | 1,192 | 1,140 |
| EBIT 1 | 578.9 | - | 351 | 454.8 | 563.8 | 688.6 | 823.9 | 978.5 |
| Operating Margin | 12.68% | - | 9.62% | 10.45% | 11.58% | 11.9% | 12.31% | 12.77% |
| Earnings before Tax (EBT) 1 | 575.4 | - | 328.3 | 445.7 | 551 | 674.4 | 811 | 966 |
| Net income 1 | 507 | - | 320.5 | 434.5 | 536.7 | 657 | 774.4 | 925 |
| Net margin | 11.1% | - | 8.79% | 9.99% | 11.03% | 11.35% | 11.57% | 12.08% |
| EPS 2 | 0.8600 | 0.4400 | 0.5600 | 0.7500 | 0.9300 | 1.123 | 1.324 | 1.583 |
| Free Cash Flow 1 | - | - | - | - | 745.6 | 232 | 903 | 925 |
| FCF margin | - | - | - | - | 15.32% | 4.01% | 13.49% | 12.08% |
| FCF Conversion (EBITDA) | - | - | - | - | 98.81% | 28.22% | 75.75% | 81.15% |
| FCF Conversion (Net income) | - | - | - | - | 138.91% | 35.31% | 116.61% | 100% |
| Dividend per Share 2 | 0.0800 | - | - | - | 0.3700 | 0.3900 | 0.4200 | 0.4500 |
| Announcement Date | 4/9/20 | 4/9/21 | 3/3/22 | 2/20/23 | 3/10/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 942.9 | 1,372 | 1,359 | 1,357 | 1,065 | 1,550 | 1,712 | 1,520 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | 134.3 | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS | 0.2300 | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 7/12/23 | 10/25/23 | 3/10/24 | 4/12/24 | - | - | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | 277 | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 0.3708 x | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | 746 | 232 | 903 | 925 |
| ROE (net income / shareholders' equity) | 12.9% | - | 7.57% | 9.61% | 10.8% | 11.1% | 12% | 12.8% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | 8.23% | 8.53% | 9.27% |
| Assets 1 | - | - | - | - | - | 7,980 | 9,084 | 9,982 |
| Book Value Per Share 2 | 6.640 | - | 7.470 | 8.130 | 8.880 | 10.00 | 11.00 | 12.30 |
| Cash Flow per Share 2 | 1.560 | - | 1.590 | 1.700 | 1.780 | 1.350 | 2.060 | 1.600 |
| Capex 1 | 449 | - | 142 | 189 | 295 | 325 | 650 | 311 |
| Capex / Sales | 9.83% | - | 3.9% | 4.35% | 6.07% | 5.61% | 9.71% | 4.06% |
| Announcement Date | 4/9/20 | 4/9/21 | 3/3/22 | 2/20/23 | 3/10/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
20.05
CNY
Average target price
25.17
CNY
Spread / Average Target
+25.55%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.29% | 1.62B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- 600557 Stock
- Financials Jiangsu Kanion Pharmaceutical Co.,Ltd.
